The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of visit number, patient expectation, and rater expectation of the efficacy of escitalopram treatment in fixed doses of 10 and 20mg, based on baseline severity in patients with MDD.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abarbanel Mental Health Center
• Collaborator: H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

1. Outpatients, men and women between 18 and 65 years of age (both extremes included)

2. DSM IV-TR criteria for a current MDE lasting between 3 and 12 months

3. Baseline MADRS total score > 22

Exclusion Criteria:

1. WHO-5 total score > 13 or a score > 3 on any single item of the WHO-5 (not revealed to the investigator)

2. Other primary or co-primary psychiatric disorder which is more distressful for the patient than MDDD, as evaluated by investigator

3. Patients with any history of mania/bipolar I disorder

4. Patients using medications which are contraindicated with the use of escitalopram

5. Known contraindication for the use of citalopram or escitalopram

6. Patients that have not responded to 2 or more treatments with an adequate dose of an antidepressant for an adequate time

7. Patients receiving formal behaviour therapy, or systematic psychotherapy

8. Unable to understand or read Hebrew and give written informed consent

9. Prominent suicidal ideation > 5 on item 10 (suicidal thoughts) of the MADRS]

10. Alcohol or substance dependence in the past 6 months